Compare GSK plc (GSK) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Lennar Corporation — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Lennar Corporation trades at $76.69 (market cap $18.44B). The key difference: GSK plc is far larger — about 5× Lennar Corporation's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Lennar Corporation for 67 Days on average.
| GSK | LEN | |
|---|---|---|
Market Cap | $91.88B | $18.44B |
Volume | 7,730,529 | 6,012,214 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $133.13 |
52-Week Low | $43.24 | $74.44 |
Typical Hold Time | 93 Days | 67 Days |
Enterprise Value | $111.88B | $22.86B |
Dividend Yield | 3.9% | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
LEN trades at $76.69, up 0.74% on the day, with a bearish technical signal from moving averages and oscillators. Recent earnings show three consecutive quarterly misses against expectations, with Q3 2026 results pending. Revenue declined to $34.19B in 2025 from $35.4B in 2024, while net income fell to $2.08B. Valuation metrics appear attractive with P/E of 14.7 and P/B of 0.86. Berkshire Hathaway has been accumulating shares, building an 11.2% stake as of October 2026.
The stock presents a value opportunity with below-book valuation and strong institutional interest, but faces headwinds from declining profitability and housing market challenges. Near-term risks include potential earnings volatility and high mortgage rates, while long-term prospects benefit from Berkshire's strategic positioning and the company's asset-light transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
